Gelonghui, May 10 | Bohui Innovation (300318.SZ) said on the investor interactive platform that the company's first quarter performance growth was mainly due to the increase in revenue and gross profit of the blood products business. The company will continue to focus on its main business, implement established strategies, pay close attention to scientific management, and continuously improve profit levels.
博晖创新(300318.SZ)：一季度业绩增长主要来自于血液制品业务的营收和毛利的增长
Bohui Innovation (300318.SZ): The increase in performance in the first quarter was mainly due to the increase in revenue and gross profit of the blood products business
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.